Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy

Lung Cancer

Volumn 86, Issue 2, 2014, Pages 268-273

  Xu, Chunhua ^a,b   Hao, Keke ^a,b   Hu, Huidi ^a   Sheng, Zhihong ^a   Yan, Jun ^c   Wang, Qingbo ^d   Yu, Like ^a,b  

^a NANJING CHEST HOSPITAL   (China)

^b Center for Diseases Control of Nanjing   (China)

^c NANJING UNIVERSITY   (China)

^d Nanjing Second Hospital   (China)

Author keywords

Biomarker; Chemotherapy; Cisplatin; Enhancer of zeste homolog 2; Non small cell lung cancer; Prognosis

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; PARAFFIN; TRANSCRIPTION FACTOR EZH2; ANTINEOPLASTIC AGENT; EZH2 PROTEIN, HUMAN; PLATINUM; POLYCOMB REPRESSIVE COMPLEX 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR BIOPSY; BIOPSY; CANCER GRADING; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; FOLLOW UP; GENE EXPRESSION; GENETICS; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PLATINUM; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; TREATMENT OUTCOME;

EID: 84908395416     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.09.010     Document Type: Article

References (23)

1. Gu J., Ding J.Y., Lu C.L., Lin Z.W., Chu Y.W., Zhao G.Y., et al. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer 2013, 81:259-265.
2. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
4. Scagliotti G.V., De Marinis F., Rinaldi M., Crinò L., Gridelli C., Ricci S., et al. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol 2009, 4:1568-1571.
5. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016-3024.
6. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747-2754.
7. Kim H.T., Lee J.E., Shin E.S., Yoo Y.K., Cho J.H., Yun M.H., et al. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol 2008, 26:5972-5979.
8. Park K.S., Kim H.K., Lee J.H., Choi Y.B., Park S.Y., Yang S.H., et al. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol 2010, 136:493-502.
9. Hussein Y.R., Sood A.K., Bandyopadhyay S., Albashiti B., Semaan A., Nahleh Z., et al. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol 2012, 43:1638-1644.
10. Bachmann I.M., Halvorsen O.J., Collett K., Stefansson I.M., Straume O., Haukaas S.A., et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006, 24:268-273.
11. Kikuchi J., Takashina T., Kinoshita I., Kikuchi E., Shimizu Y., Sakakibara-Konishi J., et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 2012, 78:138-143.
12. Huqun, Ishikawa R., Zhang J., Miyazawa H., Goto Y., Shimizu Y., et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer 2012, 118:1599-1606.
13. Kidani K., Osaki M., Tamura T., Yamaga K., Shomori K., Ryoke K., et al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 2009, 45:39-46.
14. Takawa M., Masuda K., Kunizaki M., Daigo Y., Takagi K., Iwai Y., et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 2011, 102:1298-1305.
15. Wagener N., Macher-Goeppinger S., Pritsch M., Hüsing J., Hoppe-Seyler K., Schirmacher P., et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 2010, 10:524.
16. Rizzo S., Hersey J.M., Mellor P., Dai W., Santos-Silva A., Liber D., et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 2011, 10:325-335.
17. Lv Y., Yuan C., Xiao X., Wang X., Ji X., Yu H., et al. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma. Oncol Rep 2012, 28:147-154.
18. Kassis E.S., Vaporciyan A.A., Swisher S.G., Correa A.M., Bekele B.N., Erasmus J.J., et al. Application of the revised lung cancer staging system (IASLC staging project) to a cancer center population. J Thorac Cardiovasc Surg 2009, 138:412-418.
19. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
20. He L.J., Cai M.Y., Xu G.L., Li J.J., Weng Z.J., Xu D.Z., et al. Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer. Asian Pac J Cancer Prev 2012, 13:3173-3178.
21. Behrens C., Solis L.M., Lin H., Yuan P., Tang X., Kadara H., et al. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res 2013, 19:6556-6565.
22. Hu S., Yu L., Li Z., Shen Y., Wang J., Cai J., et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 2010, 10:788-795.
23. Ougolkov A.V., Bilim V.N., Billadeau D.D. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 2008, 14:6790-6796.